Alchemia misses primary endpoint
About the author:
- Author name:
- By Scott Power
- Job title:
- Senior Analyst
- Date posted:
- 27 October 2014, 10:00 AM
- Sectors Covered:
- Healthcare, Life Sciences
Alchemia Limited (ACL) has announced that it has missed primary endpoint for its pivotal Phase III trial for the treatment of metastatic colorectal cancer.
This is a major disappointment and the share price will come under significant selling pressure today. We recommend clients urgently review their holdings with the increased risk of ACL now being unsuitable for many investor's portfolios.
We reduce our share price target to A$0.19 (previously A$0.88).
More information
Morgans clients should login to view more detailed analysis on Alchemia. Alternatively, for more information contact your adviser or nearest Morgans office.
Disclaimer(s): Analyst owns shares.
The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents ("Morgans") do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.
-
Print this page
-
Copy Link